Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.32 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893638 | 0.85 | PTGS2 (0.41) | ENPP2ORAI1ORAI2ORAI3KDM4E | |
| SCHEMBL3465794 | 0.78 | ENPP2 (0.56) | ENPP2ORAI1ORAI2ORAI3KDM4E | |
| SCHEMBL14118994 | 0.78 | ADRA1A (0.37) | HSD17B10 | |
| SCHEMBL17221783 | 0.75 | ELANE (0.53) | ELANE | |
| SCHEMBL924510 | 0.75 | RXFP1 (0.40) | BRD4 | |
| SCHEMBL3825559 | 0.74 | ENPP2 (0.36) | ENPP2ORAI1ORAI2ORAI3 | |
| SCHEMBL9893607 | 0.74 | ELANE (0.41) | ELANEENPP2 | |
| SCHEMBL840950 | 0.73 | ENPP2 (0.32) | ENPP2ORAI1ORAI2ORAI3HSD17B10 | |
| SCHEMBL5899432 | 0.73 | TSHR (0.36) | ENPP2ORAI1ORAI2ORAI3KDM4E | |
| SCHEMBL15455586 | 0.73 | ALDH1A1 (0.39) | KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ELANE 4000/4885ENPP2 147/4885ORAI1 2016/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ELANE 4000/4885ENPP2 147/4885ORAI1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.